In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model.

Abstract

Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Ery(s)) and -intermediate (Ery(i)) enterococci (ABT 50% protective doses [PD(50)s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Ery(r)) strains for which ABT MICs were low, ABT showed much greater activity (PD(50), 6.3 to 32.5 mg/kg) than ERY (PD(50), >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

• Authors: Suresh R Pai, Kavindra V Singh, Barbara E Murray
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 47 Issue 8 Pg. 2706-9 (Aug 2003) ISSN: 0066-4804 [Print] United States
• PMID: 12878548 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Ketolides
• Erythromycin
• cethromycin

Topics

• Animals
• Colony Count, Microbial
• Enterococcus faecium (drug effects)
• Erythromycin (analogs & derivatives, pharmacology, therapeutic use)
• Gram-Positive Bacterial Infections (drug therapy, microbiology)
• Ketolides
• Lethal Dose 50
• Mice
• Mice, Inbred ICR
• Microbial Sensitivity Tests
• Peritonitis (drug therapy, microbiology)